Oppenheimer Holdings, Inc. Increases Chemed Corp. (CHE) Price Target to $225.00
Chemed Corp. (NYSE:CHE) had its price objective raised by investment analysts at Oppenheimer Holdings, Inc. from $220.00 to $225.00 in a research note issued to investors on Friday. The firm currently has an “outperform” rating on the stock. Oppenheimer Holdings, Inc.’s price target would indicate a potential downside of 3.10% from the stock’s previous close.
Other research analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Chemed Corp. from a “hold” rating to a “buy” rating and set a $216.00 price objective on the stock in a research note on Monday, September 18th. TheStreet cut shares of Chemed Corp. from a “b+” rating to a “c+” rating in a research note on Tuesday, July 25th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $208.00 price objective on shares of Chemed Corp. in a research note on Wednesday, July 5th. Finally, BidaskClub cut shares of Chemed Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $216.67.
Shares of Chemed Corp. (NYSE CHE) traded up 9.82% during trading on Friday, reaching $232.20. The company’s stock had a trading volume of 139,522 shares. Chemed Corp. has a 1-year low of $132.92 and a 1-year high of $233.50. The company’s 50-day moving average price is $200.95 and its 200 day moving average price is $199.75. The stock has a market capitalization of $3.71 billion, a price-to-earnings ratio of 57.60 and a beta of 1.13.
Chemed Corp. (NYSE:CHE) last posted its quarterly earnings results on Thursday, October 26th. The company reported $2.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.15. Chemed Corp. had a net margin of 4.62% and a return on equity of 27.49%. The firm had revenue of $417.40 million during the quarter, compared to analyst estimates of $414.34 million. During the same quarter in the prior year, the business posted $1.73 earnings per share. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. Analysts anticipate that Chemed Corp. will post $8.21 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Oppenheimer Holdings, Inc. Increases Chemed Corp. (CHE) Price Target to $225.00” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/28/oppenheimer-holdings-inc-increases-chemed-corp-che-price-target-to-225-00.html.
In other Chemed Corp. news, Director Patrick P. Grace sold 500 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $201.48, for a total value of $100,740.00. Following the sale, the director now directly owns 4,515 shares in the company, valued at $909,682.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Spencer S. Lee sold 1,000 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $197.46, for a total transaction of $197,460.00. Following the completion of the sale, the insider now owns 37,809 shares in the company, valued at $7,465,765.14. The disclosure for this sale can be found here. 4.90% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Acrospire Investment Management LLC acquired a new stake in Chemed Corp. in the second quarter worth $120,000. Pacad Investment Ltd. raised its holdings in Chemed Corp. by 250.0% in the second quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock worth $143,000 after purchasing an additional 500 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Chemed Corp. by 12.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock worth $150,000 after purchasing an additional 83 shares during the period. Campbell & CO Investment Adviser LLC acquired a new stake in Chemed Corp. in the second quarter worth $209,000. Finally, World Asset Management Inc acquired a new stake in Chemed Corp. in the second quarter worth $216,000. Institutional investors own 96.94% of the company’s stock.
Chemed Corp. Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.